Medicament for treating coronary disease and stenocardia and preparation method thereof

A technology for angina pectoris and coronary heart disease, applied in the field of medicine and its preparation, can solve the problems of liquid medicine leakage, complicated production process of soft capsules, and low yield of finished products, so as to improve solubility and absorption, and the production process is simple and controllable , the effect of comprehensive cost reduction

Active Publication Date: 2010-05-12
XIAN CHIHO PHARMA
View PDF1 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] The above-mentioned chemical drugs can basically control the acute attack stage of the disease at present, and the effect is to relieve or reduce the attack of angina pectoris, but it cannot completely solve the problem of coronary artery stenosis and the problem of atherosclerosis in this disease.
Patent No.: ZL03134404.6; Invention Name: A drug for treating coronary heart disease and angina pectoris and its preparation method, disclosing a drug prescription composition of soft capsules for treating coronary heart disease and angina pectoris and its preparation method. At present, there are strict requirements on storage cond

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicament for treating coronary disease and stenocardia and preparation method thereof
  • Medicament for treating coronary disease and stenocardia and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] The present embodiment raw material weight component comprises following medicine:

[0023] 20 parts of total flavonoids of kudzu root, 6 parts of hawthorn extract, 2 parts of gypenosides, 16 parts of hydroxypropyl β-cyclodextrin, 4 parts of calcium hydrogen phosphate, 10 parts of pregelatinized starch, 1.0 parts of croscarmellose sodium part, 0.2 part of micronized silica gel.

[0024] Its raw material weight component of the present embodiment is made up of following medicine:

[0025] 20 parts of total flavonoids of kudzu root, 6 parts of hawthorn extract, 2 parts of gypenosides, 16 parts of hydroxypropyl β-cyclodextrin, 4 parts of calcium hydrogen phosphate, 10 parts of pregelatinized starch, 1.0 parts of croscarmellose sodium part, 0.2 part of micronized silica gel.

[0026] The preparation method steps of the present embodiment are as follows:

[0027] 1. Weigh 6 parts of hawthorn extract with total flavonoids greater than 2.0% based on rutin and a particle siz...

Embodiment 2

[0031] The present embodiment raw material weight component comprises following medicine:

[0032] 20 parts of total flavonoids of kudzu root, 6 parts of hawthorn extract, 2 parts of gypenosides, 20 parts of hydroxypropyl β-cyclodextrin, 6 parts of calcium hydrogen phosphate, 12 parts of pregelatinized starch, 1.4 parts of croscarmellose sodium part, 0.3 part of micronized silica gel.

[0033] Its raw material weight component of the present embodiment is made up of following medicine:

[0034] 20 parts of total flavonoids of kudzu root, 6 parts of hawthorn extract, 2 parts of gypenosides, 20 parts of hydroxypropyl β-cyclodextrin, 6 parts of calcium hydrogen phosphate, 12 parts of pregelatinized starch, 1.4 parts of croscarmellose sodium part, 0.3 part of micronized silica gel.

[0035] The preparation method steps of the present embodiment are as follows:

[0036]1. Weigh 6 parts of hawthorn extract with a total flavonoids greater than 2.0% based on rutin and a particle si...

Embodiment 3

[0040] The present embodiment raw material weight component comprises following medicine:

[0041] 20 parts of total flavonoids of kudzu root, 6 parts of hawthorn extract, 2 parts of gypenosides, 24 parts of hydroxypropyl β-cyclodextrin, 8 parts of calcium hydrogen phosphate, 14 parts of pregelatinized starch, 1.6 parts of croscarmellose sodium part, 0.4 part of micronized silica gel.

[0042] Its raw material weight component of the present embodiment is made up of following medicine:

[0043] 20 parts of total flavonoids of kudzu root, 6 parts of hawthorn extract, 2 parts of gypenosides, 24 parts of hydroxypropyl β-cyclodextrin, 8 parts of calcium hydrogen phosphate, 14 parts of pregelatinized starch, 1.6 parts of croscarmellose sodium part, 0.4 part of micronized silica gel.

[0044] The preparation method steps of the present embodiment are as follows:

[0045] 1. Weigh 6 parts of hawthorn extract with total flavonoids greater than 2.0% based on rutin and a particle siz...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Granularityaaaaaaaaaa
Granularityaaaaaaaaaa
Login to view more

Abstract

The invention provides a medicament for treating coronary disease and stenocardia and a preparation method thereof. The method comprises the following steps: 1, putting 6 parts of hawthorn extract into a cavity of a granulator, adding 5 to 15 parts of hydroxypropyl beta cyclodextrin and 4 to 10 parts of calcium monohydrogen phosphate by weight into the cavity, stirring the mixture at high speed, injecting ethanol into the cavity, stirring the mixture once again, granulating the mixture and drying the granules; 2, putting 20 parts of pueraria flavonid and 2 parts of gypenosides by weight in a mixture, adding the mixture of 10 to 15 parts of pregelatinized starch and 0.7 to 1.4 parts of croscarmellose sodium in a material cavity of a one-step granulator, injecting hydroxypropyl beta cyclodextrin ethanol solution into the material cavity of the granulator, drying the materials for 1 hour after feed liquid is injected, and stabilizing the granules for later use; and 3, adding the granules into the mixture, adding 0.3 to 0.6 part of the croscarmellose sodium and 0.2 to 0.6 part of superfine silica powder into the mixture for mixing and tableting, coating the tablets with films or filling the tablets, and subpackaging the tablets. The medicament prepared by the method has remarkable curative effect and long quality guarantee period.

Description

technical field [0001] The invention relates to a medicine and a preparation method thereof, in particular to a medicine for treating coronary heart disease and angina pectoris and a preparation method thereof. Background technique [0002] Coronary heart disease and angina pectoris refer to clinical syndromes caused by coronary insufficiency, acute and temporary myocardial ischemia and hypoxia. The principle of treatment for coronary heart disease and angina pectoris is to improve the blood supply of the coronary arteries and reduce the oxygen consumption of the myocardium, while treating atherosclerosis. Therapeutic drugs are divided into three categories. [0003] Category 1: Nitrate preparations, the main function is to dilate coronary arteries, reduce resistance, increase blood flow in coronary circulation, reduce cardiac preload and myocardial oxygen demand, and relieve angina pectoris. Commonly used preparations are nitroglycerin, isoamyl nitrite, pentyl tetranitrat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K36/734A61K47/40A61P9/10
Inventor 田继堂胡小虎
Owner XIAN CHIHO PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products